Abstract

Oncology services utilize about 15% of the blood transfusion resources in the USA. Red blood cell transfusion is performed immediately before, during or after major surgery to compensate for blood loss and hemodilution. However, a lack of evidence-based guidelines leads to variable transfusion practices among clinicians. The benefits of transfusing blood products are obvious in life-threatening low blood cell counts or bleeding, but it is becoming apparent that deliberate blood transfusion in some cancer patients can trigger negative clinical impacts. This review attempts to provide an overview of the impact of red blood cell transfusion in patients suffering from various types of oncologic pathologies.

Original languageEnglish
Pages (from-to)287-290
Number of pages4
JournalTransfusion and Apheresis Science
Volume56
Issue number3
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Erythrocyte Transfusion
Blood Transfusion
Hemodilution
Blood Cell Count
Neoplasms
Guidelines
Pathology
Hemorrhage

Keywords

  • Cancer
  • Prognosis
  • Recurrence
  • Red blood cells
  • Transfusion

ASJC Scopus subject areas

  • Hematology

Cite this

Iqbal, N., Haider, K., Sundaram, V., Radosevic, J., Burnouf, T., Seghatchian, J., & Goubran, H. (2017). Red blood cell transfusion and outcome in cancer. Transfusion and Apheresis Science, 56(3), 287-290. https://doi.org/10.1016/j.transci.2017.05.014

Red blood cell transfusion and outcome in cancer. / Iqbal, Nayyer; Haider, Kamal; Sundaram, Vinita; Radosevic, Julia; Burnouf, Thierry; Seghatchian, Jerard; Goubran, Hadi.

In: Transfusion and Apheresis Science, Vol. 56, No. 3, 01.06.2017, p. 287-290.

Research output: Contribution to journalReview article

Iqbal, N, Haider, K, Sundaram, V, Radosevic, J, Burnouf, T, Seghatchian, J & Goubran, H 2017, 'Red blood cell transfusion and outcome in cancer', Transfusion and Apheresis Science, vol. 56, no. 3, pp. 287-290. https://doi.org/10.1016/j.transci.2017.05.014
Iqbal N, Haider K, Sundaram V, Radosevic J, Burnouf T, Seghatchian J et al. Red blood cell transfusion and outcome in cancer. Transfusion and Apheresis Science. 2017 Jun 1;56(3):287-290. https://doi.org/10.1016/j.transci.2017.05.014
Iqbal, Nayyer ; Haider, Kamal ; Sundaram, Vinita ; Radosevic, Julia ; Burnouf, Thierry ; Seghatchian, Jerard ; Goubran, Hadi. / Red blood cell transfusion and outcome in cancer. In: Transfusion and Apheresis Science. 2017 ; Vol. 56, No. 3. pp. 287-290.
@article{21911bb3ed144d3fb88a16ec0ee44bcd,
title = "Red blood cell transfusion and outcome in cancer",
abstract = "Oncology services utilize about 15{\%} of the blood transfusion resources in the USA. Red blood cell transfusion is performed immediately before, during or after major surgery to compensate for blood loss and hemodilution. However, a lack of evidence-based guidelines leads to variable transfusion practices among clinicians. The benefits of transfusing blood products are obvious in life-threatening low blood cell counts or bleeding, but it is becoming apparent that deliberate blood transfusion in some cancer patients can trigger negative clinical impacts. This review attempts to provide an overview of the impact of red blood cell transfusion in patients suffering from various types of oncologic pathologies.",
keywords = "Cancer, Prognosis, Recurrence, Red blood cells, Transfusion",
author = "Nayyer Iqbal and Kamal Haider and Vinita Sundaram and Julia Radosevic and Thierry Burnouf and Jerard Seghatchian and Hadi Goubran",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.transci.2017.05.014",
language = "English",
volume = "56",
pages = "287--290",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Red blood cell transfusion and outcome in cancer

AU - Iqbal, Nayyer

AU - Haider, Kamal

AU - Sundaram, Vinita

AU - Radosevic, Julia

AU - Burnouf, Thierry

AU - Seghatchian, Jerard

AU - Goubran, Hadi

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Oncology services utilize about 15% of the blood transfusion resources in the USA. Red blood cell transfusion is performed immediately before, during or after major surgery to compensate for blood loss and hemodilution. However, a lack of evidence-based guidelines leads to variable transfusion practices among clinicians. The benefits of transfusing blood products are obvious in life-threatening low blood cell counts or bleeding, but it is becoming apparent that deliberate blood transfusion in some cancer patients can trigger negative clinical impacts. This review attempts to provide an overview of the impact of red blood cell transfusion in patients suffering from various types of oncologic pathologies.

AB - Oncology services utilize about 15% of the blood transfusion resources in the USA. Red blood cell transfusion is performed immediately before, during or after major surgery to compensate for blood loss and hemodilution. However, a lack of evidence-based guidelines leads to variable transfusion practices among clinicians. The benefits of transfusing blood products are obvious in life-threatening low blood cell counts or bleeding, but it is becoming apparent that deliberate blood transfusion in some cancer patients can trigger negative clinical impacts. This review attempts to provide an overview of the impact of red blood cell transfusion in patients suffering from various types of oncologic pathologies.

KW - Cancer

KW - Prognosis

KW - Recurrence

KW - Red blood cells

KW - Transfusion

UR - http://www.scopus.com/inward/record.url?scp=85020135079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020135079&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2017.05.014

DO - 10.1016/j.transci.2017.05.014

M3 - Review article

VL - 56

SP - 287

EP - 290

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 3

ER -